More Concern About Transfusion Requirement When Evaluating Quality of Life in Anemic Patients-Reference-Cited by-同舟云学术

More Concern About Transfusion Requirement When Evaluating Quality of Life in Anemic Patients

Published:2002-07-15 Issue:14 Volume:20 Page:3182-3184
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Oliva Esther N.,D’Angelo Arianna,Martino Bruno,Nobile Francesco,Dimitrov Borislav D.¹,Perna Annalisa,Gabrilove Janice L.,Sarokhan Brenda,Cremieux Pierre

Affiliation:

1. Azienda Ospedaliera “Bianchi-Melacrino-Morelli”, Reggio Calabria, Italy

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2002.20.14.3182

Reference5 articles.

1. Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly Dosing

2. Thomas ML: Quality of life and psychosocial adjustment in patients with myelodysplastic syndromes. Leuk Res 1001: S41,1998-S47,

3. Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34: 13,1997-19,

4. Oliva EN, Dimitrov BD, D’Angelo A, et al: QOL-E: A new tool for the assessment of quality of life (QOL) in myelodysplastic syndrome (MDS). Blood 98: 427a,2001 (abstr)

5. Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly Dosing

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists;Blood Advances;2021-12-30

2. Comparisons of commonly used front-line regimens on survival outcomes in patients aged 70 years and older with acute myeloid leukemia;Haematologica;2019-05-09

3. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents;Journal of Clinical Oncology;2016-09-01

4. Anemia as the Main Manifestation of Myelodysplastic Syndromes;Seminars in Hematology;2015-10

5. Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence;Cancer Medicine;2015-09-17